Literature DB >> 2012763

Reduction of platelet glycoprotein Ib in uraemia.

E M Sloand1, J A Sloand, K Prodouz, H G Klein, M W Yu, L Harvath, W Fricke.   

Abstract

Patients with uraemia have abnormal platelet function that may be partially corrected by haemodialysis, cryoprecipitate or 1-desamino-8-D-arginine vasopressin (DDAVP). We studied the platelet von Willebrand factor receptor, glycoprotein Ib (GPIb), and plasma von Willebrand factor (vWF) in uraemic patients undergoing chronic haemodialysis. Using the slope of agglutination of formalin-fixed platelets as an index of response to ristocetin (with a constant amount of normal plasma as a source of vWF), we found the response of platelets from uraemic patients, both before (2.7 +/- 1.5, n = 40) and after dialysis (1.2 +/- 1.2, n = 40) to be significantly less than that for normal controls (14.1 +/- 10.2, n = 20; P less than 0.001). In addition, the agglutination response of platelets obtained after dialysis was less than that of platelets obtained before dialysis (P less than 0.001). Immunoblotting demonstrated decreased or absent staining of glycocalicin, a subunit of GPIb, in platelet lysates from 25 patients. All platelet samples with reduced glycocalicin also had decreased responses to ristocetin. Tritium-labelled platelets from seven patients showed decreased labelling of a protein with an electrophoretic mobility equivalent to that of GPIb (140,000 daltons). In addition, platelets with the lowest levels of surface GPIb, as demonstrated by flow cytometry, also had decreased ristocetin agglutination and decreased staining on immunoblot. Levels of von Willebrand factor antigen and ristocetin cofactor in plasma from 10 patients were generally within the normal range, although postdialysis levels tended to be higher than pre-dialysis levels. The pre- and post-dialysis plasma vWF multimeric patterns were normal.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2012763     DOI: 10.1111/j.1365-2141.1991.tb08587.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  5 in total

Review 1.  [Thrombocytopathy and blood complications in uremia].

Authors:  Walter H Hörl
Journal:  Wien Klin Wochenschr       Date:  2006-04       Impact factor: 1.704

Review 2.  Oral antiplatelet drugs in patients with chronic kidney disease (CKD): a review.

Authors:  Homam Ibrahim; Sunil V Rao
Journal:  J Thromb Thrombolysis       Date:  2017-05       Impact factor: 2.300

Review 3.  Hemostatic complications in renal disorders of the young.

Authors:  M Andrew; L A Brooker
Journal:  Pediatr Nephrol       Date:  1996-02       Impact factor: 3.714

4.  Platelet thrombus formation in patients with end-stage renal disease before and after hemodialysis as measured by the total thrombus-formation analysis system.

Authors:  Branka P Mitic; Zorica M Dimitrijevic; Kazuya Hosokawa; Tatjana P Cvetkovic; Milan V Lazarevic; Danijela D Tasic; Andriana Jovanovic; Nina Jancic; Tamara Vrecic; Anna Ågren; Håkan Wallen
Journal:  Int Urol Nephrol       Date:  2022-04-02       Impact factor: 2.266

5.  Elevated levels of procoagulant plasma microvesicles in dialysis patients.

Authors:  James O Burton; Hassan A Hamali; Ruchir Singh; Nima Abbasian; Ruth Parsons; Amit K Patel; Alison H Goodall; Nigel J Brunskill
Journal:  PLoS One       Date:  2013-08-02       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.